APPROACHES Protocol Version 1.3 Date : July 15, 2025 
 APPROACHES: ALIGNING PATIENT PREFERENCES ‚Äì A ROLE 
OFFERING ALZHEIMER‚ÄôS PATIENTS, CAREGIVERS, AND 
HEALTHCARE PROVIDERS EDUCATION AND SUPPORT  
 
A Nursing Home Pragmatic Clinical Trial  
 
Principal Investigator s: 
Susan Hickman, PhD 
Clinical Geropsychologist & Professor 
Indiana University School of Nursing 
 
Kathleen Unroe, MD, MHA 
Geriatrician & Associate Professor  
Regenstrief Institute  
Indiana University Center for Aging Research  
 
Co-Investigator:  
Wanzhu Tu, PhD 
Biostatistician  
Regenstrief Institute  
Indiana University Center for Aging Research  
 
Supported by: 
The National Institute on Aging  
 1R21AG057463-01 
 
[STUDY_ID_REMOVED]  
  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 
  Version 1 .3  
July 15, 2025 
 TABLE OF CONTENTS  
................................................................................................................................................... Page 
TABLE OF CONTENTS  .............................................................................................................. i  
PR√âCIS  ......................................................................................................................................... iii 
Study Title .................................................................................................................................. iii 
Objectives  .................................................................................................................................. iii 
Design and Outcomes  ................................................................................................................ iii 
Sample Size and Population....................................................................................................... iii 
STUDY TEAM ROSTER  ............................................................................................................ 4 
PARTICIPATING STUDY SITES  ............................................................................................. 6 
1 STUDY OBJECTIVES  ......................................................................................................... 7 
1.1 Primary Objectives  .......................................................................................................... 7 
1.2 Secondary Objective  ....................................................................................................... 7 
2 BACKGROUND AND RATIONALE  ................................................................................. 7 
2.1 Background on Condition, Disease, or Other Primary Study Focus .............................. 7 
2.2 Study Rationale ............................................................................................................... 7 
3 STUDY DESIGN ................................................................................................................... 8 
4 SELECTION AND ENROLLMENT OF PARTICIPANTS  ............................................. 8 
4.1 Inclusion Criteria  ............................................................................................................ 9 
4.2 Exclusion Criteria  ........................................................................................................... 9 
4.3 Study Enrollment Procedures ......................................................................................... 9 
5 STUDY INTERVENTIONS  ................................................................................................. 9 
5.1 Interventions, Administration, and Duration .................................................................. 9 
6 STUDY PROCEDURES  ..................................................................................................... 10 
6.1 Description of Evaluations  ............................................................................................ 10 
6.1.1. Enrollment, Baseline, and/or Randomization .............................................................. 10 
7 SAFETY ASSESSMENTS  .................................................................................................. 10 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 ii 7.1 Adverse Events and Serious Adverse Events  ............................................................... 11 
7.2 Safety Monitoring  ......................................................................................................... 12 
8 INTERVENTION DISCONTINUATION  ........................................................................ 14 
9 STATISTICAL CONSIDERATIONS  ............................................................................... 15 
9.1 General Design Issues  ................................................................................................... 15 
9.2 Sample Size and Randomization  .................................................................................. 15 
9.3 Interim analyses and Stopping Rules  .................................................................................. 16 
9.4 Outcomes  ............................................................................................................................ 16 
9.4.1 Primary outcome  ....................................................................................................... 16 
9.4.2 Secondary outcomes  ................................................................................................. 16 
9.5 Data Analyses  ..................................................................................................................... 16 
10 DATA COLLECTION AND QUALITY ASSURANCE  ............................................ 17 
10.1 Data Management  ......................................................................................................... 17 
10.2 Quality Assurance  ......................................................................................................... 17 
10.3.1 Training ...................................................................................................................... 17 
10.3.2 Quality Control Committee  ....................................................................................... 17 
10.3.3 Metrics  ...................................................................................................................... 17 
10.3.4 Protocol Deviations  ................................................................................................... 17 
10.3.5 Monitoring  ................................................................................................................ 18 
11 PARTICIPANT RIGHTS AND CONFIDENTIALITY  ............................................. 18 
11.1 Institutional Review Board (IRB) Review  .................................................................... 18 
11.2 Informed Consent Forms  .............................................................................................. 18 
11.3 Participant Confidentiality  ............................................................................................ 18 
11.4 Study Discontinuation  ................................................................................................... 19 
12 ETHICAL CONSIDERATIONS  ................................................................................... 19 
13 COMMITTEES ............................................................................................................... 19 
14 PUBLICATION OF RESEARCH FINDINGS  ............................................................ 21 
15 REFERENCES  ................................................................................................................ 23 
 
  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 iii PR√âCIS   
Study Title  
APPROACHES: Aligning Patient Preferences ‚Äì a Role Offering Alzheimer‚Äôs patients, 
Caregivers, and Healthcare providers Education and Support   
 
Objectives  
APPROACHES  is a pragmatic cluster randomized control trial testing the impact of a 
structured ACP specialist program on patients with Alzheimer‚Äôs and dementia related diseases in nursing homes.  1.1 Primary Objective R33 Phase (42 months)  
1.1.1  Aim 1: Compare hospital transfers (admissions and emergency department 
visits)  over 12 months  between ADRD patients in intervention vs. control 
nursing home s 
1.2.1.1   H1: Transfers will be lower among ADRD patients in intervention 
vs. control nursing home s. 
1.2 Secondary Objective  
1.2.1  Aim 2: Compare the following secondary outcomes between ADRD 
patients in intervention vs. control nursing home s over 12 months: 1) hospice 
enrollment; and 2) death in hospital . 
1.2.2.1 H1: ADRD patients in the intervention vs. control nursing home s will 
have:  
1.2.2.1.1 i. Greater hospice enrollment;  
1.2.2.1.2 and ii. Lower rates of dying in the hospital.  
 Design and Outcomes   
In intervention nursing home s, a nursing home  provider (e.g. social worker  or chaplain ) 
will be trained as an ACP Specialist who will work with nursing home  leaders to: i. 
Consolidate nursing home  ACP procedures; ii. Train and educate staff; and iii. Facilitate 
ACP with patients and their family caregivers. Control nursing home s will apply the 
usual ACP practices. The implementation period will be 18 months. All ADRD patients in the nursing home s during the implementation will be followed for 12 months.  
 
Sample Size and Population  
A total of 142  nursing home s will be  randomized to either an intervention or control arm 
within each corporation (Signature, N= 109; Miller‚Äôs, N= 3 3).  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 4 STUDY TEAM ROSTER  
Co-Principal Investigator:        Susan Hickman, PhD  
 600 Barnhill Drive  
 Indianapolis, IN 46202 
 (317) 274- 0032 
 hickman@iu.edu 
 Main responsibilities /Key roles : Leading the project  
 
Co-Principal Investigator:        Kathleen Unroe, MD, MHA  
 1101 West 10th Street  
 Indianapolis, IN 46202 
 (317) 274- 9227 
 kunroe@iu.edu 
 Main responsibilities/Key roles: Leading the project  
 
Co-Investigator:           Wanzhu Tu, PhD  
 1101 West 10th Street  
 Indianapolis, IN 46202 
 (317) 278- 6451 
 wtu@iu.edu  
 Main responsibilities /Key roles: Data m anagement & a nalysis  
 
Consultant :                 Susan Mitchell, MD, MPH  
 1200 Centre Street  
 Boston, MA 02131 
 (617) 971- 5326 
 smitchell@hsl.harvard.edu 
 Main responsibilities/Key roles: Reviewing material, providing resources  
 
Consultant:       Laura Hanson, MD, MPH  
 5003 Old Clinic  
 Chapel Hill, NC  
 (919) 843- 4096 
 laura_hanson@med.unc.edu 
 Main responsibilities/Key roles: Consulting, reviewing 
material, providing resources  
 
Project Coordinators/ Manager s: Laramie Mack  (from 2018 to April 2024)  
 1101 West 10
th Street  
 Indianapolis, IN 46202 
 (317) 274- 9126 
 lbrewer@regenstrief.org  
 Main responsibilities/Key roles: Project management  
 
Abigail Evans (from April 2024 to present)  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 5  1101 West 10th Street  
 Indianapolis, IN 46202 
 (317) 274- 9059 
 abievans@regenstrief.org 
 Main responsibilities/Key roles: Project coordination  
 
  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 6 PARTICIPATING STUDY SITES  
Indiana University School of Nursing 
600 Barnhill Dr.  Indianapolis, IN 46202 (317) 274- 0032 
hickman@iu.edu  Regenstrief Institute, Inc.  
1101 W. 10
th St.  
Indianapolis, IN 46202 (317) 274- 9227 
kunroe@iu.edu   Miller‚Äôs Health System  
1690 S. County Farm Rd.,  Warsaw, IN 46508 Alaina  Butiste, Corporate Representative  
abutiste@millershealthsystems.com  
   Signature HealthCARE  
12201 Bluegrass Pkwy., Louisville, KY 40299  
Katy Wane, Assistant Chief Compliance & Ethics Officer  
Kwane@signaturehealthcarellc.com  
   
APPROACHES Protocol Version 1.3 Date : July 15, 2025 7 1 STUDY OBJECTIVES  
1.1 Primary  Objectives  
1.1.1  Aim 1: Compare hospital transfers (admissions and emergency department 
visits)  over 12 months  between ADRD patients in intervention vs. control 
nursing homes.  
1.2.1.1   H1: Transfers will be lower among ADRD patients in intervention vs. 
control nursing home s. 
1.2 Secondary Objective  
1.2.1  Aim 2: Compare the following secondary outcomes between ADRD patients in 
intervention vs. control nursing homes over 12 months: 1) hospice enr ollment 
and 2) death in hospital. 
1.2.2.1  H1: ADRD patients in the intervention vs. control nursing home s will have:  
1.2.2.1.1 i. Greater hospice enrollment;  
1.2.2.1.2 and ii. Lower rates of dying in the hospital.  
 
2 BACKGROUND AND RATIONALE  
2.1 Background on Condition, Disease, or Other Primary Study Focus 
A significant number of patients Alzheimer‚Äôs disease or related dementia diagnoses will 
be cared for in nursing homes near the end of life. Unfortunately, many of these patients experience unwanted and burdensome medical treatments, such as potentially avoidable hospitalizations, that negatively impact quality of life. Advance care planning (ACP) discussions with patients  and family caregivers are important to explore goals in advance 
of a crisis and support informed, values- based decision -making. The ACP process helps 
to ensure that preferences about treatments such as hospitalization are known, 
documented, and honored. R esearch indicates that ACP can reduce burdensome 
treatments and increase the likelihood that care will match documented preferences. Nursing homes are currently required by regulations to offer ACP to patients and families. However, there are no training requirements for nursing home staff and approaches to fulfilling this regulatory and ethical responsibility vary widely, resulting in inconsistent ACP. The ‚ÄúAligning Patient Preferences ‚Äì a Role Offering Alzheimer‚Äôs patients, Caregivers, and Healthcare prov iders Education and Support (APPROACHES)‚Äù 
trial will test the ACP Specialist Program. Existing nursing home staff members will be trained to enhance care and reduce unwanted, burdensome hospitalizations through improved ACP procedures, standardized staff education on ACP, and systematic ACP facilitation.  
 
2.2 Study Rationale  
The ACP Specialist Training courses will serve as an educational tool to  provide training 
to the ACP Specialists at enrolled nursing facilities that engage in ACP conversations. This tool will help refine and improve their knowledge of how to best have and record these conversations by providing tips, examples, and information on nursing homes.  A majority (72%) of nursing home patients have cognitive impairment
1 and about half 
have a documented diagnosis of Alzheimer‚Äôs Disease or a related dementia (ADRD).2 As 
a result of the progressive, downward trajectory of ADRD,3 70% of patients live their 
final days in nursing home s.4 These patients often receive burdensome and expensive 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 8 treatments that may be avoidable and even unwanted.5,6 Hospitalizations are increasingly 
identified as a concern because of high burdens, high costs, and low clinical benefits in 
patients with advanced stages of dementia.7 Advance care planning (ACP) provides 
family caregivers of ADRD patients with education and support in identifying and documenting goals of care to align treatments with preferences.
8 Documentation 
reflecting preferences for less aggressive treatment is associated with lower rates of hospitalization.
9,10,11 However, nursing home staff are rar ely trained to facilitate ACP or 
provided with strategies to integrate into practice resulting in highly variable practice and inaccurate documentation.
6,7,12- 18 
 Under the auspices of a Centers for Medicare and Medicaid Services Initiative, our team has developed and successfully implemented a multi -component intervention to reduce 
avoidable hospitalizations of long-stay patients in 19 nursing home s across Indiana.
19,20 
While the scalability and sustainability of the full intervention model remains untested, our experience to date indicates the ACP component is particularly practical, effective, and translatable. The proposed ACP Specialist Program will build on this foundation by refining the ACP component to target ADRD patients and their family caregivers. This intervention will be delivered by existing nursing home  staff (e.g., social worker).  
 The over- riding objective of this proposal is to conduct a pragmatic cluster randomized 
controlled trial (RCT) of ‚ÄúAligning Patient Preferences ‚Äì a Role Offering Alzheimer‚Äôs patients, Caregivers, and Healthcare providers Ed ucation and Support (APPROACHES) ‚Äù 
that aims to improve ACP and goal-directed outcomes in nursing home patients with ADRD. In the R33 phase, we will conduct the full pragmatic RCT in partnership with 2 nursing home corporations (Signature HealthCARE  and Miller‚Äôs Health Systems) in  a 
combi ned total of 142 diverse facilities in 8 states. Consistent with the spirit of a 
pragmatic trial, we will use existing data sources including electronic health records (EHR), the Minimum Data Set 3.0 (MDS), and Medicare Claims data to characterize the cohort and measure outcomes. Hospital transfers over 12 months among ADRD patients is the 1
o trial outcome.  
 
3 STUDY DESIGN 
A total of 142  nursing home s will be randomized to either an intervention or control arm 
within each corporation (Signature, N= 109; Miller‚Äôs, N= 33 ). In intervention nursing 
home s, a nursing home provider (e.g. social worker) will be trained as an ACP Specialist 
who will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients and their family caregivers. Control nursing home s will apply the usual ACP practices. The 
implementation period is expe cted to  be 18 months. All ADRD patients in the nursing 
homes during the implementation will be followed for 12 months.  
4 SELECTION AND ENROLLMENT OF PARTICIPANTS   
Facilities will be randomized to either the control arm or the intervention arm. This selection will take into account the choice of each organization considering half the organizations facilities are included in each arm.    
APPROACHES Protocol Version 1.3 Date : July 15, 2025 9 The focus of the ACP Specialist will be patients with ADRD who reside in the nursing 
homes during the initiative, though other  patients residing in the nursing home may 
benefit from it in keeping with the spirit of a pragmatic trial.21 Only patients with ADRD 
will be included in the analysis. ADRD is defined to include cognitive impairment1 or a 
documented diagnosis of dementia in the MDS. Patients will be excluded if they are currently enrolled in hospice at the start of the intervention period . 
 Eligible facilities who agree to participate in the trial will be stratified at two levels: corporate ownership (Signature HealthCARE  and Miller‚Äôs Health Systems ) & average 
number of hospital transfers per 1000 person-days alive using 2017 MDS data provided by CMS . Facilities will be grouped into low versus high hospitalization rates, using the 
median rate for the nursing home system as the threshold value for dichotomization. 
Facilities will be randomized to the intervention or control within each strata a t a 1-to-1 
ratio. Specifically, randomization will occur at the facility level, meaning that all patients with ADRD in the intervention buildings are eligible for inclusion in the trial. Following random assignment, we will use all available facility and p atient -level data to test the 
balance of the intervention and control arms.   Nursing home characteristics will be obtained from nursing home  corporate partners and 
the MDS. Potentially eligible nursing home s will be reviewed by the Data Management 
and Analysis Workgroup in preparation for potential inclusion in the pragmatic cluster RCT. Problematic or unstable facilities will be removed in consultation with nursing home corporate leaders prior to randomization.  
 
4.1 Inclusion Criteria  
‚Ä¢ Medicare- certified  
‚Ä¢ All residents with Alzheimer‚Äôs disease and related dementias. 
‚Ä¢ > 50 licensed beds  
‚Ä¢ >50% of residents are long-stay (>100 days in the facility) 
4.2 Exclusion Criteria  
‚Ä¢ Patients currently enrolled in hospice at the start of the intervention period  
‚Ä¢ Problematic or unstable nursing homes   
‚Ä¢ Defined by corporate leadership prior to randomization 
4.3 Study Enrollment Procedures  
‚Ä¢ Enrollment is occurring at the facility level; individual patients are not being 
enrolled. 
 
5 STUDY INTERVENTIONS   
5.1 Interventions, Administration, and Duration  
Following randomization, the ACP Specialist program will be rolled out to the 
intervention buildings. All communications will be tailored to fit the corporate branding style of Signature  HealthCARE  and Miller‚Äôs Health Systems . Communications about the 
ACP Specialist Program with individual facilities will be delivered by the Corporate Implementation Champion and the designated ACP Specialists, with , at minimum,  
monthly meetings with the project team to discuss issues and any unmet needs. At the conclusion o f the pragmatic cluster RCT, we will merge our data and analyze to measure 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 10 our primary and secondary outcomes. 
6 STUDY PROCEDURES  
6.1 Description of Evaluations  
6.1.1. Enrollment, Baseline, and/or Randomization  
Nursing home  Eligibility : All Medicare -certified nursing homes are eligible at 
Signature HealthCARE and Miller‚Äôs Health Systems.  
 
Nursing home  Recruitment & Characteristics:  
The ACP Specialist Program will be rolled out as a corporate initiative and nursing 
home Executive Directors will be requested to participate in the initiative by nursing home corporate leadership. It is anticipated all nursing home Executive Directors who are approached will agree to participate.  
 Nursing home  corporate partners each provided data about key nursing home 
characteristics.  At the time of randomization Signature HealthCARE owns 1 09 
nursing homes in 8 states, with a total of 8,811 beds; 43% are rural. Miller‚Äôs Health Systems owns 3 3 nursing homes, all in Indiana with 3,066 beds; 55% are rural. The 
mix of rural and urban facilities will provide a rich environment for this pragmatic trial. Self-reported 30-day hospital readmission rates for 2016 range from 13% for Miller‚Äôs  Health Systems  and 17% for Signature HealthCARE nursing home s. 
 
Random Assignment : Nursing homes will be sorted  into groups that are comparable 
on hospital transfer rates. Eligible facilities who agree to participate in the trial will be stratified at two levels: corporate ownership (Signature  HealthCARE  and Miller‚Äôs 
Health Systems) & average number of hospital transfers per 1000 person- days alive 
using 2017 MDS  data. Facilities will be grouped into low versus high hospitalization 
rates, using the median rate for the nursing home system as the threshold value for dichotomization. Facilities will be randomized to the  intervention or control within 
each strata at a 1 -to-1 ratio. Specifically, randomization will occur at the facility level, 
meaning that all patients not currently on hospice at the start of the intervention period in the intervention buildings are eligible for inclusion in the trial.  The 
intervention focuses on patients with ADRD, but other residents of intervention facilities are not excluded. Following random assignment, we will use all available 
facility and patient -level data to test the balance of th e intervention and control arms.  
 
7 SAFETY ASSESSMENTS    
IRB has determined this study to be minimal risk.  
 Although this study includes a vulnerable population of patients with cognitive impairment, it is anticipated that this study will be determined to represent no more than minimal risk to patients and family caregivers. All nursing homes are required to off er 
ACP to patients and family caregivers as part of routine care. This requirement is inclusive of patients with cognitive impairment or ADRD. Therefore, the ACP Specialist Program is consistent with the standard of care and the risk of harm is no greater than those ordinarily encountered in the daily life of a nursing home patient or family caregiver who may be offered the opportunity to engage in ACP by nursing home staff. 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 11 According to 45 CFR 46.102 (OHRP 2017),22 research is considered to pose minimal risk 
if the likelihood and degree of harm or discomfort anticipated from the research is no 
greater than that ordinarily encountered during daily life . 
 
7.1 Adverse Events and Serious Adverse Events  
An adverse event (AE)  is generally defined as any unfavorable and unintended 
diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline, appears to wor sen.  
 A serious adverse event (SAE)  is generally defined as any untoward medical occurrence 
that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congeni tal anomaly.  
 
The potential serious negative reaction (SNR) that could occur during this trial is serious 
patient or family caregiver distress when engaging in ACP with the ACP Specialist. Based on our experience and results from other research studies, we anticipate th at this 
will be rare. Serious distress could be demonstrated by negative reactions such as anger, 
uncontrolled crying, or early termination of an ACP discussion with the Specialist. The 
nature of these discussions is sensitive and personal, thus expression s of emotion, 
including tears, is expected and would not be considered a SNR. Training of the ACP 
Specialist will include emphasis on the importance of asking permission to begin an ACP 
conversation and respecting patient and family refusals. It will also include provision of 
emotional support and empathic statements during discussions. ACP Specialist training 
will include recognition of SNRs and instruction. In the R33 phase, staff will be 
instructed to report any negative reactions immediately to the Exec utive Director and the 
nursing home Corporate Implementation Champion. Together, these health care 
providers will evaluate the severity of the event and, if deemed serious, will report the 
SNR to the research team project manager via email or fax within 24  hours of the event. 
The project manager will report the SNR to both co -PIs via email or telephone 
immediately upon becoming aware of the event and will also notify the TBN Data and Safety Monitoring Board (DSMB) Chair in writing (email and hard copy) with in 48 
hours. The Co- PIs will take ultimate responsibility for ensuring the DSMB chair is 
informed in a timely manner. Follow -up includes checking in with the patient or family 
caregiver within 6 to 24 hours of the initial SNR to assess whether further inte rvention is 
needed to mitigate the SNR. If necessary, the patient or family caregiver should be 
referred for follow -up (e.g., referring family caregiver to primary care provider or 
community mental health facility).  
 
We do not believe any potential consequences of APPROACHES would be considered 
serious adverse events (SAEs). We do not believe that death should be considered an 
SAE for this trial as: 1) death is often not unexpected in this nursing home population 
with ADRD; 2) death is not an adverse outcome for patients and families with goals of comfort or palliation if those goals are met; and 3) it is not known whether or not 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 12 aggressive care provided at the hospital results in lower mortality compared with 
conservative care in the nursing home.   In this pragmatic trial, we will work closely with the nursing home corporate partners deploying the intervention in order to monitor the overall safety of patients in the project, minimize any risk associated with the research, and protect confidentiality. After the initiation of the R33, the nursing home Corporate Implementation Champions and nursing home Corporate Data Experts from each of the 2 nursing home partners will participate in monthly meetings to discuss project implementation and address questions, problems, or concerns that might arise, including data safety and risk to patients.   Co-PIs Hickman and Unroe will continue to actively monitor for any results of other new 
research studies or regulatory policies that may have an impact on APPROACHES. Further, we will request the DSMB members to monitor for any external scientific or therapeutic developments that could impact the ethics of the trial or safety of participants  
 
7.2 Safety Monitoring  
The Co -PI Hickman will be responsible for executing the DSMP in her role as the lead 
for the Regulatory and Operations Workgroup. Co- PI Unroe, the project manager , data 
manager, information technology (IT) support person, and the IT representatives for each of the t wo partner institutions will all participate in the Regulatory and Operations 
Workgroup. This workgroup will also be responsible for obtaining appropriate agreements for nursing home health system partners, including Memoranda of Understanding (M OU) and Data Use Agreements (DUA) prior to any data transfer. This 
workgroup has oversight of submission of CMS data requests, that must include all data 
security precautions, as well as submission of the protocol to the Indiana University 
Indianapolis (IUI) Institutional Review Board (IRB) for review and approval. The Regulatory and Operations workgroup will also support the coordination of DSMB. All study personnel, including PIs, Co-Is, consultant, project manager, and nursing home Corporate Implementati on Champions will complete online education in the Protection of 
Human Research Practice and complete Conflict of Interest Forms. Our DSMP will be included as part of the research protocol and submitted to the IUI IRB.  
Frequency of Data and Safety Monitoring. 
During the intervention phase of the R33 trial, nursing home Corporate Implementation Champions will be charged with asking nursing home based ACP Specialists about any adverse events and unanticipated problems that may have occurred in the course of their role. The nursing home Corporate Implementation Champions will meet at least monthly with the project team during the intervention phase. Any adverse events and unanticipated problems requiring immediate action will be discussed immediately with either of the PIs to determine necessary corrective action. Problems not requiring 
immediate actions will be addressed during monthly research team meeting and at quarterly DSMB meetings. Outcome of adverse events and unanticipated problems will be periodically rep orted to the IRB and the NIH. 
 
Content of Data and Safety Monitoring Report 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 13 A Data and Safety Monitoring Report will be prepared once a year and will include 
status, participant descriptive information, safety information, and fidelity monitoring.  
 
Data and Safety Monitoring Board Membership  
DSMB membership will include experts or representatives of the field with relevant clinical expertise, clinical trials methodology, and biostatistics. The members will be selected by the National Institute on Aging (NIA) program officer in consultation with the Co -PIs. 
 
Conflict of Interests  
Members of the DSMB shall have no direct involvement with the study investigators or nursing home corporate partners. Each DSMB member will sign the IU Conflict of Interest Statement, which include current affiliations and any other relationships that could be perceived as a conflict of interest related to the study.  
Protection of Confidentiality  
Data will be presented in a blinded manner with no participant or nursing home identifiers. All materials, discussions, and proceedings of the DSMB will be completely confidential and DSMB members are expected to maintain confidentiality.  
 
DSMB Responsibilities  
The DSMB will be formed in consultation with the NIA program officer and will include 2-3 external members. According to NIA guidance, the Chair will be selected by the NIA. The DSMB Chair will serve as the safety officer for the project and will be responsible for running meetings. The DSMB will be charged with monitoring patient 
safety, data quality and overall performance of the study. Responsibilities will include 
review of the research protocol, with a focus on protecting patient confidentiality and the plan for data and safety monitoring. Review of performance will include progress towards milestones, evaluation of recruitment, assessment of any serious negative reactions, and identification of issues around data storage or quality. The DMSB will also advise the NIA on the readiness of the trial to initiate recruitment, progress of the trial, and review of study performance including making recommendations and/or assisting in the resolution of problems identified by the Co -PIs. The DMSB will report to the NIA on 
the safety and progress of the trial as well as commenting on any problems with study conduct, enrollment, sample size, and/or data collection. All adverse events and unanticipated problems occurring during the course of the study will be collected, documented, and reported to the PIs and the DSMB Chair. These will be reported to NIA Project Officer and IRB quarterly. The PIs will meet with the study team staff weekly and at least one of the Co -PIs will be available at all times via email or phone . Serious 
adverse events potentially related to the intervention will be reported to both the Chair of the DSMB and to the NIA Project Officer within 24 hours of either PI learning of the issue. The DSMB Chair will determine if an additional meeting of the  DSMB is needed 
and convene.   
APPROACHES Protocol Version 1.3 Date : July 15, 2025 14 8 INTERVENTION DISCONTINUATION  
Adverse Event and Serious Adverse Event Collection and Reporting. 
The potential adverse event (AE)  that could occur during this trial is significant distress 
by patients or family members in the intervention NHs. Such events may be the 
manifestation of a very negative emotional reaction during a facilitated ACP discussion including uncontrolled crying or complaining to facility leadership. Due to the sensitive nature of the material, tearing up, crying, expressions of emotion, or early termination of the conversation by the proxy can be expected during advance care planning and are not deemed to be adverse events. The risk of potential distress caused by exposure to the ACP Specialist Program is no greater than the risk of distress from experiencing these conversations in routine clinical care.  
Training of the ACP Specialist will include emphasis on the importance of asking permission to begin an ACP conversation and respecting patient and family refusals. It will also include provision of emotional support and empathic statements during discussi ons. ACP Specialist training will include recognition of AEs and instructions. In 
the R33 phase, staff will be instructed to report any negative reactions immediately to the Executive Director and the nursing home Corporate Implementation Champion. Instructions are provided to the ACP Specialists and Corporate Implementation Champions about what constitutes an adverse event. In the event of an AE, ACP Specialists will report the event to his/her immediate supervisor, who will report it to the Corporate Impl ementation Specialist. Together, these professionals will determine the 
severity of the event and if it is a true AE related to the ACP Specialist Program. If deemed necessary, the Corporate Implementation Champion will notify the research project staff within 48 hours of the event.   
The project manager will report the AE to both co -PIs via email or telephone 
immediately upon becoming aware of the event and will also notify the TBN Data and 
Safety Monitoring Board (DSMB) Chair in writing (email and hard copy) within 48 
hours. The Co- PIs will take ultimate responsibility for ensuring the DSMB chair is 
informed in a timely manner. Follow -up includes checking in with the patient or family 
caregiver within 6 to 24 hours of the initial AE to assess whether further intervention is 
needed to m itigate the AE. If necessary, the patient or family caregiver should be referred 
for follow -up (e.g., referring family caregiver to primary care provider or community 
mental health facility). A summary of any AEs will be reported quarterly to the NIA 
program officer and the IRB.  
 
We do not believe any potential consequences of APPROACHES would be considered 
serious adverse events (SAEs). We do not believe that death should be considered an 
SAE for this trial as: 1) death is often not unexpected in this nursing home population 
with ADRD; 2) death is not an adverse outcome for patients and families with goals of 
comfort or palliation if those goals are met; and 3) it is not known whether or not 
aggressive care provided at the hospital results in lower mortality compared with 
conservative care in the nursing home. 
 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 15 In this pragmatic trial, we will work closely with the nursing home corporate partners 
deploying the intervention in order to monitor the overall safety of patients in the project, 
minimize any risk associated with the research, and protect confidentiality. After the 
initiation of the R33, the nursing home Corporate Implementation Champions and 
nursing home Corporate Data Experts from each of the 2 nursing home partners will 
participate in monthly meetings to discuss project implementation and address questions, 
problems, or concerns that might arise, including data safety and risk to patients.  
 
Co-PIs Hickman and Unroe will continue to actively monitor for any results of other new 
research studies or regulatory policies that may have an impact on APPROACHES. 
Further, we will request the DSMB members to monitor for any external scientific or 
therapeutic developments that could impact the ethics of the trial or safety of participants.  
 
 
9 S TATISTICAL CONSIDERATIONS   
9.1 General Design Issues  
The over- riding objective of this proposal is to conduct a pragmatic cluster-randomized 
controlled trial (RCT) of ‚ÄúAligning Patient Preferences ‚Äì a Role Offering Alzheimer‚Äôs 
patients, Caregivers, and Healthcare providers Education and Support (APPROACHES)‚Äù that aims to improve ACP and goal-directed outcomes in nursing home patients with ADRD. In the R33 phase, we will conduct the full pragmatic RCT in partnership with 2 nursing home corporations (Signature HealthCARE and Miller‚Äôs Health Systems) who operate a combined total of 142 diverse facilities in 8 states. Consistent with the spirit of 
a pragmatic trial, we will use existing data sources including electronic health records (EHR), the Minimum Data Set 3.0 (MDS),  and Medicare Claims data to characterize the 
cohort and measure outcomes. Hospital transfers over 12 months among ADRD patients is the 1
o trial outcome.  
 
9.2 Sample Size and Randomization 
Power Calculations.  The implementational advantages of cluster RCT are gained at the expense of reduced analytical power, as compared to a simple RCT.
23 Reduction of power is proportional to 
the intracluster correlation (ICC) coefficient ùúåùúå , which represents the strength of 
correlation among subjects within the same cluster. The within- cluster correlation has a 
correlate ‚Äì the between cluster variation, which is commonly expressed as the coefficient of variation (CV).
24   Larger ICC or CV values will lead to bigger variance inflation and 
more power loss.   A power analysis was conducted  using preliminary data from the Minimum Data Set 
(MDS) provided by CMS. We estimated that the between -cluster CV would be less  than 
0.5. Assuming that the two  treatment arms have similar CV values of a similar 
magnitude, we calculated the power for detecting 20% reduction in rate of hospital admission by the proposed intervention. Our analysis showed that with 12 0 facilities ( 60 
per arm) and an average of 50 residents per facility , we will have 81% power to detect a 
20% difference in the rate of hospitalization (1.0 per resident year in the control group vs 0.8 per resident year in the intervention group), by using a Poisson regression analysis 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 16 with 0.05 level  of significance.  We note that the power estimate is likely to be 
conservative because in the actual analysis, we plan to control for the effects of the 
covariates; the reduced variability explained by the covariates will increase the power.   
   
 
9.3 Interim analyses and Stopping Rules  
We will not be conducting an interim analysis or developing rules for stopping the trial early for several reasons. The planned intervention of a trained ACP Specialist who will augment usual care is unlikely to cause harm. The IRB has determined that this study is minimal risk.  Particularly given the delay in obtaining Medicare claims for determining 
the primary outcome, hospitalization or emergency department visits, it will not be feasible to determine the differences in this outcome between the interven tion and control 
groups until the end of the 12 month outcome observation period.    
9.4 Outcomes  
9.4.1 Primary outcome   
9.4.1.1 Hospital transfers over 12 months among ADRD patients  
9.4.2 Secondary outcomes   
9.4.2.1 Hospice enrollment  over 12 months among ADRD patients  
9.4.2.2 Death in hospital  over 12 months among ADRD patients  
 
9.5 Data Analyses  
Design consideration. The R33 phase of the study has two aims: (Aim 1 ‚Äì Primary) To 
compare hospital transfers (admissions and emergency department visits)  over 12 months 
between ADRD patients in the intervention and control facilities; and (Aim 2 - 
Secondary) assess the interventional effect of the ACP Specialist Program on hospice enrollment and place of death. Towards these ends, we employ a cluster RCT design. With this design, randomization will be carried out at the nursing home  level, stratified 
by nursing home  corporate ownership and baseline hospitalization transfer rates (low 
versus high) . All patients at a given nursing home  will have the same intervention 
assignment . The trial outcomes will be analyzed  at the individual patient level  and 
reported at the facility level. The cluster RCT with nursing home  randomization is chosen 
because of its ability to simultaneously maximize the implementational feasibility and minimize the contamination risk.
25,26 Counts of hospital transfers and emergency 
department visits incurred by individual ADRD patients during the follow -up period will 
be considered as the primary outcome. We designed the trial to ensure adequate power for the hypothesis concerning the primary outcome. Average age and proportion of female patients is similar across our nursing home  partner facilities and the U.S. The % 
of Black patients ranges from 6 -17% across the population of our partner nursing home s. 
About half of nursing home  patients have a dementia diagnosis. This is similar for our 
partner facilities.  
 Analysis will be carried out in an intention -to-treat (ITT) framework, which gives a 
pragmatic estimate of the interventional benefit.
27 The ITT analysis will use data from all 
eligible patients in randomized facilities, regardless of the level of facilities‚Äô adherence to the study protocol and patient attrition. ITT is a preferred approach for pragmatic trials 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 17 because the analysis generates estimates of treatment effectiveness in a more realistic 
way. In fact, clinical effectiveness can be severely overestimated if ITT analysis is not performed .
28 Within the ITT framework, we propose to analyze the trial data using 
appropriate generalized linear models. Specifically, we plan to compare the rates of 
hospital admissions in patients residing in the intervention vs control facilities.  In line 
with intention -to-treat principles and our cluster randomized design, hospi talizations will 
be analyzed at the facility level, including for residents who moved across intervention and control buildings during the study period. Group assignment will be based on the facility each resident was first admitted to during the intervention period.  Thus, some 
residents may have a documented ACP encounter in intervention facilities but also spent some time in control facilities.  The analysis will be carried out using an appropriate count 
data regression model, length of observation will be adjusted as an offset parameter. We will test the levels of extra -Poisson variation to determine if a Poisson regression model 
is sufficient for the analysis. If the level of variation is beyond what can be accommodated by the Poisson model, we will consi der using negative binomial 
regression. Similarly, we will test the presence of extra zeros that beyond the Poisson or 
negative binomial models. If necessary we will consider the use of zero -inflated Poisson 
or negative binomial regression analysis. Correlations among outcomes measured from residents in the same facility will be accounted for by adding random facility effects into the regression models. This analytical approach handles missing data (early dropout due to death or transfer to hospice) more easily because of the inclusion of offsetting parameters in the model.  
 
10 DATA COLLECTION AND QUALITY ASSURANCE  
10.1 Data Management  
The proposed study will combine multiple sources of patient data to measure impact on the quality of care near the end -of-life.  
 
10.2 Quality Assurance  
10.3.1 Training 
ACP Specialists will complete standardized training via modules created for the study and available in their learning management systems. Corporate representatives and corporate implementation champions will complete a corresponding training adapted for ke y leaders via modules created for the study and available in their learning 
management systems.  
10.3.2 Quality Control Committee  
Not applicable. 
10.3.3 Metrics  
Provide quality control metrics for outcome measures.  
10.3.4 Protocol Deviations 
Protocol deviations will be assessed in monthly meetings with the corporate implementation champions.  Since this is a pragmatic trial, we anticipate and have 
built- in flexibility in implementation of the ACP specialist program that would not be 
considered a protocol deviation. 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 18 10.3.5 Monitoring  
Monitoring will occur via review of the monthly data transfer and through monthly 
meetings with the corporate implementation champions.   
 
11 PARTICIPANT RIGHTS AND CONFIDENTIALITY  
11.1 Institutional Review Board (IRB) Review  
The proposed study has been  reviewed by the Indiana University Institutional Review 
Board (IRB), which will serve as the centralized, single IRB for the trial in accordance with National Institutes of Health policy. This trial is  registered at clinicaltrials.gov  
([STUDY_ID_REMOVED]) . A Data Safety and Management Plan is described in this protocol . 
 
11.2 Informed Consent Forms  
A wavier of informed consent was  sought from the IRB. This pragmatic clinical trial 
meets the criteria for a waiver of informed consent as described in 45 CRF 46:116. Specifically: 1) this research represents no more than minimal risk; 2) a waiver does not adversely affect the rights and  welfare of participants; 3) the research could not be 
practicably carried out without the waiver; and 4) information will be provided to the nursing home  partners after the trial to share with interested patients and family  
caregivers.
29 Patient and family caregiver refusals to participate in ACP discussion will 
be honored.  
11.3 Participant Confidentiality  
Data provided by nursing home  corporate partners (MDS, EHR) will be transferred using 
HIPAA compliant, encrypted processes. CMS (Claims, MDS) and EHR data files will be securely stored using processes developed to meet CMS data requirements as part of a prior CMS data request. Specifi cally, data will be stored on a virtual server administered 
by Indiana University‚Äôs Clinical Affairs IT Service (CAITS) team. The virtual server is located on Indiana University‚Äôs Intelligent Infrastructure on hardware that is physically located in two ent erprise -class machine rooms in separate physical locations. The server 
rooms require biometric authentication in addition to a chip -based access card and are 
staffed 24x7x365 and feature video security. Network firewall rules are used to restrict server access to only necessary subnets. Only IU domain workstations with security controls (auto logoff , centralized threat management, host -based firewall, and more) will 
be permitted to connect to the virtual server. Each study team member with access to the CMS  data must use a passphrase. Protocols are in place dictating that passphrases must 
be at least 15 characters in length with at least 4 unique characters (letters, numbers, and symbols ) and use at least 4 words separated by spaces or other non -letters. Password 
reuse is restricted, not allowing the previous 2 passwords to be reused. Sessions on workstations and servers, whether local or remote, are locked after being idle for 15 minutes  and terminated after 24 hours of non- use. 
 The systems used to store and analyze the data will be subjected to a documented NIST -
based risk management process prior to receipt and use of the requested data. The process is briefly outlined below:  
 a) Inventory assets‚Äîhardware, software, personnel.  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 19 b) Document controls‚Äîidentify every existing and appropriate NIST 800-53 control for 
the system. NIST 800-53 (an industry and government standard) is a comprehensive catalog of 926 security controls. NIST 800-66 (a mapping of the HIPAA security rule to NIST 800- 53) is used to identify appropriate controls for electronic Personal Health 
Information. c) Assess risk ‚Äîidentify risks that existing control address and residual risk from missing 
controls.  
d) Respond to risk-how each residual risk is addressed (mitigated, transferred or accepted), explanation/justification, and timelines for mitigation, if any. e) Establish ongoing risk management‚Äîsemi -annual reviews and documentation 
updates, external assessments.  
f) Training -two annual HIPAA training courses (University general course and an IT-
specific course).  
 
11.4 Study Discontinuation  
The study may be discontinued at any time by the IRB, the NIA, the OHRP, the FDA, or other government agencies as part of their duties to ensure that research participants are protected.   
12 ETHICAL CONSIDERATIONS  
Protections against Risk  
Informed consent will not be sought from patients or family caregivers for this  pragmatic 
cluster randomized control trial.30 Strategies to minimize risk to participants are based on 
the experiences of the study PI and Co-Is in conducting research on ACP and in the 
nursing home setting. Additionally, Dr.  Hickman has expertise in ethical issues in 
research with these populations to inform both study design and strategies to protect 
against risk. Dr. Hickman has previously conducted research on ethical issues in 
conducting long- term care research31,32 and NIH- funded research on ethical issues in end -
of-life research.33 
 
13 CO MMITTEES  
Executive Committee: The Executive Committee will oversee all aspects of project development, implementation, and analysis including human resources, communications with the National Institutes of Health, and budgetary decisions.   Steering Committee: The Steering Committee will include the Co -PIs Hickman and 
Unroe, Co- I Tu, Consultant s Mitchell and Hanson, and representatives from each nursing 
home corporate partner. This group will be responsible for overseeing the project direction, ensuring close collaboration between APPROACHES and nursing home partners, coordinating workgroup tasks, and meeting project milestones. This includes transition to the R33 phase. The Steering Committee will also be responsible for reviewing EHRs to ens ure existing fields adequately capture relevant ACP data to guide 
clinical care (e.g., allow for documentation of specific POLST form orders and not just code status) with the goal of standardization of documentation across sites and the creation of clinic ally useful dashboards. 
 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 20 Regulatory and Operations Workgroup: This workgroup will be led by Co- PI Hickman, 
with Co -PI Unroe, the p roject manager, data manager, information technology (IT) 
support, and nursing home  Corporate Data Experts. This Workgroup will be responsible 
for obtaining signed Memoranda of Understanding as well as a signed Data Use 
Agreements (DUA) from each corporate nursing home  partner and ensuring data are 
transferred safely. This Workgroup will prepare and submit the CMS data request outlining all data security  precautions along with related institutional policies. Because of 
the close link between data security and issues related to patient and family caregiver confidentiality, this workgroup will be responsible for oversight of the human subjects‚Äô protections. This include d submitting an application to the Indiana University 
Institutional Review Board (IU IRB), which will serve as the IRB of record, and requesting a waiver of informed consent for patients and family caregivers . Finally, this 
group will oversee the implementation of the Data Safety and Monitoring plan, which includes developing the Data Safety and Monitoring Board (DSMB) charter, convening the DSMB, and supporting its work (see Section F).  APPROACHES Intervention Protocol Workgroup: This group will be responsible for implementation in the R33 phase. It will be led by Co -PI Hickman with Co -PI Unroe, 
Consultant Hanson, the Project Manager , and representatives from the partner 
organizations.   The ACP Specialist Program is based on the successful OPTIMISTIC nurse role but adapted for use by internal nursing home  staff. The ACP Specialist Program will be 
implemented as a new nursing home  initiative. Corporate policies regarding ACP 
practices will be reviewed and potentially modified or developed in collaboration with 
our nursing home  partners to support roll out of this new initiative. Signature  
HealthCARE  and Miller‚Äôs Health Systems corporate leadership have expressed 
willingness to make policy or procedure modifications necessary to support the ACP Specialist Program. Similar to OPTIMISTIC, a process will be developed to ensure the staff member designated as the ACP Specialist is assigned a group of 10 ADRD patients each month to approach about A CP with accountability for reporting to local nursing 
home  leadership. The intervention will be refined in collaboration with nursing home  
partners and current OPTIMISTIC nurses. Any modifications will be based on consensus, and rely on national standards and existing evidence from research. Meetings will first be held separately with Signature  HealthCARE  and Miller‚Äôs Health Systems corporate 
leadership to identify opportunities and potential barriers within each system. The program will be refined based on this feedback followed by a smaller, combined meeting with representatives from each organization to review and finalize.  
 The ACP Specialist Program include s a brief online training for Executive Directors, 
Medical Directors, and Directors of Nursing (approximately 1 hour for each). The materials have been tailored to each nursing home  corporation electronic learning 
platform and brand standards. The goals of this training are: a review of ACP and its importance, particularly for patients with ADRD and their families; an understanding of the ACP Specialist Program and role; and to conve y the importance of support for the 
ACP S pecialist dedicated role as a key nursing home  staff position. Nursing  home  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 21 leadership will be expected to offset the ACP Specialist‚Äôs new responsibilities by 
permanently shifting work to other staff.  
 The nursing home  staff member designated as the ACP Specialist will complete a longer 
training (approximately 7  hours) and will receive a hard -copy manual including sample, 
educational handouts and access to videos for patients, families, and other nursing home staff, documentation instructions, tracking tools, and tips for navigating common barriers. Due to the COVID-19 pandemic and its significant impact on NHs, an Introductory Launch Course was created for ACP Specialists to complete prior to implementation at 
their facility with the understanding that all  additional training modules would then be 
completed. The training will include specific information about decision -making for 
patients with dementia. Training materials are anticipated to include OPTIMISTIC educational tools created by Dr. Hickman and materials developed by Dr. Hanson. Core expectations include review and modification of ACP procedures as needed, education provided to other nursing home staff, and dedicated time to coordinate and facilit ate ACP 
discussions with ADRD patients and/or family caregivers using the target assignment list. Based on experience with OPTIMISTIC, the ACP Specialist will require a minimum of 1 day per week (20% FTE) initially, with a reduction over time after the initial start -up 
work. Dedicated time and schedule flexibility are critical to the success of the ACP Specialist to reach family caregivers and facilitate conversations.  
 Consistent with the principles of a pragmatic trial, instructions about how to implement the protocol role will be highly flexible.
34 For example, some facilities may decide to 
train more than one ACP Specialist within the building to share responsibilities. There is also flexibility in level of expertise required by practitioners delivering the intervention 
so the ACP Specialist may be any staff person deemed qualified by the nursing home 
Executive Director to fulfill the role, though it is anticipated it will likely be a social worker or a nurse. It is expected that there will be adaptations to the ACP tools and educational materials a s needed.  
 Data Management and Analysis Workgroup: This group will be led by Co- PI Unroe with 
Co-I Tu, Co-PI Hickman, Co-I Mitchell, biostatistician, data manager, and IT Support. 
This group is responsible for the data management required to link data sources in preparation for analysis as well as the analysis itself. In order to assess our outcome measures to both justify the adequacy of these measures and finalize these variables, a subset of MDS and Claims file records will be compared to the nursing home EHR in collaboration with our clinical partners to determine whether the process of merging was 
accurate. For example, validity checks will be performed to see if all hospital transfers are captured.  
 
14 PUBLICATION OF RESEARCH FINDINGS  
Publication of the results of this trial will be governed by the policies and procedures developed by the Steering Committee. Any presentation, abstract, or manuscript will be made available for review by the sponsor and the NIA prior to submission. Publication authorship will be based on the relative scientific contributions of the PIs, key personnel, and nursing home  corporate partners (e.g., nursing home Corporate Implementation 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 22 Champion).  
 
  
APPROACHES Protocol Version 1.3 Date : July 15, 2025 23 15 REFERENCES  
1. Thomas KS, Dosa D, Wysocki A, Mor V. The Minimum Data Set 3.0 Cognitive 
Function Scale. Medical Care. 2015. 
2. Centers for Disease Control. Alzheimer's Disease. 2016; https://www.cdc.gov/nchs/fastats/alzheimers.htm, 2016. Accessed January 24, 2017.  
3. Larson EB, Shadlen MF, Wang L, et al. Survival after Initial Diagnosis of Alzheimer Disease. Annals of Internal Medicine. Apr 6 2004;140(7):501- 509. 
4. Mitchell SL, Teno JM, Miller SC, Mor V. A National Study of the Location of Death for Older Persons with Dementia. Journal of the American Geriatrics Society. Feb 2005;53(2):299- 305. PMID: 15673356. 
5. Fillenbaum G, Heyman A, Peterson B, Pieper C, Weiman A. Use and Cost of Hospitalization of Patients with Ad by Stage and Living Arrangement Cerad Xxi. Neurology. 2001;56(2):201- 206. 
6. Morrison RS, Siu AL. Survival in End- Stage Dementia Following Acute Illness. JAMA 
: the Journal of the American Medical Association. 2000;284(1):47- 52. 
7. Mitchell SL, Teno JM, Intrator O, Feng Z, Mor V. Decisions to Forgo Hospitalization in Advanced Dementia: A Nationwide Study. Journal of the American Geriatrics Society. 2007;55(3):432- 438. PMID: 17341248. 
8. Mezey M, Dubler N, Bottrell M, et al. Guidelines for End- of-Life Care in Nursing 
Facilities: Principles and Recommendations. New York: New York University Division of Nursing, the John A. Hartford Foundation Institute for Geriatric Nursing and the Montefiore Medical Center Division of Bioethics. 2001.  
9. Hickman SE, Keevern E, Hammes BJ. Use of the Physician Orders for Life‚Äê Sustaining 
Treatment Program in the Clinical Setting: A Systematic Review of the Literature. Journal of the American Geriatrics Society. 2015;63(2):341- 350. PMID: 25644280. 
10. Hammes BJ, Rooney BL, Gundrum JD, Hickman SE, Hager N. The Polst Program: A 
Retrospective Review of the Demographics of Use and Outcomes in One Community Where Advance Directives Are Prevalent. Journal of Palliative Medicine. 2012;15(1):77- 85. PMID: 22233467. 
11. Levy C, Morris M, Kramer A. Improving End- of-Life Outcomes in Nursing Homes by 
Targeting Residents at High Risk of Mortality for Palliative Care: Program Description and Evaluation. Journal of Palliative Medicine. 2008;11(2):217- 225. 
12. Mitchell SL, Teno JM, Kiely DK, et al. The Clinical Course of Advanced Dementia. The New England journal of medicine. Oct 15 2009;361(16):1529- 1538.2778850. 
PMID: 19828530. 
13. Mitchell SL, Kiely DK, Hamel MB. Dying with Advanced Dementia in the Nursing Home. Archives of Internal Medicine. Feb 9 2004;164(3):321- 326. PMID: 14769629. 
14. Engel SE, Kiely DK, Mitchell SL. Satisfaction with End ‚Äêof‚ÄêLife Care for Nursing 
Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 2006;54(10):1567- 1572. PMID: 17038076. 
15. Ahronheim JC, Morrison RS, Baskin SA, Morris J, Meier DE. Treatment of the Dying in the Acute Care Hospital: Advanced Dementia and Metastatic Cancer. Archives of Internal Medicine. 1996;156(18):2094- 2100. 
16. Teno JM, Clarridge BR, Casey V, et al. Family Perspectives on End -of-Life Care at the 
Last Place of Care. JAMA : the Journal of the American Medical Association. Jan 7 2004;291(1):88- 93. 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 24 17. Hanson LC, Carey TS, Caprio AJ, et al. Improving Decision- Making for Feeding 
Options in Advanced Dementia: A Randomized, Controlled Trial. Journal of the 
American Geriatrics Society. Nov 2011;59(11):2009- 2016.PMC3227016. 
18. Kiely DK, Givens JL, Shaffer ML, Teno JM, Mitchell SL. Hospice Use and Outcomes in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 2010;58(12):2284- 2291. PMID: 21143437. 
19. Unroe KT, Sachs GA, Dennis M, et al. Effect of Hospice Use on Costs of Care for 
Long‚Äê Stay Nursing Home Decedents. Journal of the American Geriatrics Society. 
2016;64(4):723- 730. PMID: 27059000. 
20. Hickman SE, Unroe KT, Ersek MT, Buente B, Nazir A, Sachs GA. An Interim Analysis 
of an Advance Care Planning Intervention in the Nursing Home Setting. Journal of the American Geriatrics Society. 2016;64(11):2385 -2392. 
21. Thorpe KE, Zwarenstein M, Oxman AD, et al. A Pragmatic ‚ÄìExplanatory Continuum 
Indicator Summary (Precis): A Tool to Help Trial Designers. Journal of Clinical 
Epidemiology. 2009;62(5):464- 475. 
22. US Department for Health and Human Services. Office for Human Research 
Protections.  https://www.hhs.gov/ohrp/. Accessed on January 24th, 2017. 
23. Connelly LB. Balancing the Number and Size of Sites: An Economic Approach to the Optimal Design of Cluster Samples. Controlled clinical trials. 2003;24(5):544 -559. 
24. Pagel C, et al.  Intracluster correlation coefficients and coefficients of variation for perinatal outcomes from five cluster- randomised controlled trials in low and middle -
income countries: results and methodological implications. Trials. 2011: 12. 151. 
25. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. Arnold London, England; 2000. 
26. Simpson JM, Klar N, Donnor A. Accounting for Cluster Randomization: A Review of Primary Prevention Trials, 1990 through 1993. American Journal of Public Health. 
1995;85(10):1378- 1383.  
27. Hollis S, Campbell F. What Is Meant by Intention to Treat Analysis? Survey of Published Randomised Controlled Trials. Bmj. 1999;319(7211):670- 674. 
28. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of Antidepressants. Meta -Analysis of Dose -Effect Relationships in Randomised Clinical 
Trials. The British Journal of Psychiatry. 1999;174(4):297 -303. 
29. Mckinney Jr RE, Beskow LM, Ford DE, et al. Use of Altered Informed Consent in Pragmatic Clinical Research. Clinical Trials. 2015;12(5):494 -502. 
30. Lantos JD, Wendler D, Septimus E, Wahba S, Madigan R, Bliss G. Considerations in the Evaluation and Determination of Minimal Risk in Pragmatic Clinical Trials. Clinical Trials. 2015;12(5):485 -493. 
31. Cartwright JC, Hickman SE. Conducting Research in Community- Based Care 
Facilities: Ethical and Regulatory Implications. Journal of Gerontological Nursing. 2007;33(10):5- 11. PMID: 17955733. 
32. Hickman SE, Cartwright JC, Young HM. Administrators' Perspectives on Ethical Issues in Long- Term Care Research. Journal of Empirical Research on Human Research 
Ethics : JERHRE. Mar 2008;3(1):69- 78. PMID: 19385784. 
33. Hickman SE, Cartwright JC, Nelson CA, Knafl K. Compassion and Vigilance: Investigators' Strategies to Manage Ethical Concerns in Palliative and End -of-Life 
Research. Journal of Palliative Medicine. 2012;15(8):880 -889. PMID: 22731516. 
APPROACHES Protocol Version 1.3 Date : July 15, 2025 25 PMCID: PMC3396150. 
34. Thorpe KE, Zwarenstein M, Oxman AD, et al. A Pragmatic ‚ÄìExplanatory Continuum 
Indicator Summary (Precis): A Tool to Help Trial Designers. Journal of Clinical 
Epidemiology. 2009;62(5):464- 475. 
 